DDInter1956 DDInter1112
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.
Zalcitabine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Zalcitabine {u} (Compound) downregulates {v} (Gene) GDF15
GDF15 {u} (Gene) is downregulated by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Zalcitabine {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Zalcitabine {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
CYP3A7-CYP3A51P {u} (Gene) is bound by {v} (Compound) Phenytoin
Phenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magaldrate
Zalcitabine {u} (Compound) downregulates {v} (Gene) GDF15
GDF15 {u} (Gene) is downregulated by {v} (Compound) Gatifloxacin
Gatifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magaldrate
Zalcitabine {u} (Compound) causes {v} (Side Effect) Oesophageal ulcer
Oesophageal ulcer {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magaldrate
Zalcitabine {u} (Compound) causes {v} (Side Effect) Rash maculo-papular
Rash maculo-papular {u} (Side Effect) is caused by {v} (Compound) Raltegravir
Raltegravir {u} may lead to a major life threatening interaction when taken with {v} Magaldrate
Zalcitabine {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Bisacodyl
Bisacodyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magaldrate
Zalcitabine {u} (Compound) downregulates {v} (Gene) MRPL19
MRPL19 {u} (Gene) is downregulated by {v} (Compound) Bisacodyl
Bisacodyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magaldrate
Zalcitabine {u} (Compound) downregulates {v} (Gene) TUBB6
TUBB6 {u} (Gene) is upregulated by {v} (Compound) Mycophenolic acid
Mycophenolic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magaldrate
Zalcitabine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Zalcitabine (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Zalcitabine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Zalcitabine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Phenytoin (Compound) and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Zalcitabine (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Gatifloxacin (Compound) and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Zalcitabine (Compound) causes Oesophageal ulcer (Side Effect) and Oesophageal ulcer (Side Effect) is caused by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Zalcitabine (Compound) causes Rash maculo-papular (Side Effect) and Rash maculo-papular (Side Effect) is caused by Raltegravir (Compound) and Raltegravir may lead to a major life threatening interaction when taken with Magaldrate
Zalcitabine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Bisacodyl (Compound) and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Zalcitabine (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is downregulated by Bisacodyl (Compound) and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Zalcitabine (Compound) downregulates TUBB6 (Gene) and TUBB6 (Gene) is upregulated by Mycophenolic acid (Compound) and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate